[HTML][HTML] Targeting HSF1 as a therapeutic strategy for multiple mechanisms of EGFR inhibitor resistance in EGFR mutant non-small-cell lung cancer
S Lee, J Jung, YJ Lee, SK Kim, JA Kim, BK Kim… - Cancers, 2021 - mdpi.com
Simple Summary We attempted to identify target proteins and compounds that can be used
to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated EGFR …
to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated EGFR …
[HTML][HTML] Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
S Lee, J Jung, YJ Lee, SK Kim, JA Kim, BK Kim… - Cancers, 2021 - ncbi.nlm.nih.gov
Although EGFR-TKI treatment of NSCLC (non-small-cell lung cancer) patients often
achieves profound initial responses, the efficacy is transient due to acquired resistance …
achieves profound initial responses, the efficacy is transient due to acquired resistance …
Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer.
S Lee, J Jung, YJ Lee, SK Kim, JA Kim, BK Kim… - Cancers, 2021 - europepmc.org
Although EGFR-TKI treatment of NSCLC (non-small-cell lung cancer) patients often
achieves profound initial responses, the efficacy is transient due to acquired resistance …
achieves profound initial responses, the efficacy is transient due to acquired resistance …
Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
S Lee, J Jung, YJ Lee, SK Kim, JA Kim, BK Kim… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Although EGFR-TKI treatment of NSCLC (non-small-cell lung cancer) patients often
achieves profound initial responses, the efficacy is transient due to acquired resistance …
achieves profound initial responses, the efficacy is transient due to acquired resistance …
Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer.
S Lee, J Jung, YJ Lee, SK Kim, J Kim, BK Kim… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: We attempted to identify target proteins and compounds that can
be used to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated …
be used to overcome EGFR-TKI resistance in NSCLC. To accomplish this, we generated …
Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
S Lee, J Jung, L Yu-Jin, K Seon-Kyu, K Jung… - …, 2021 - search.proquest.com
Although EGFR-TKI treatment of NSCLC (non-small-cell lung cancer) patients often
achieves profound initial responses, the efficacy is transient due to acquired resistance …
achieves profound initial responses, the efficacy is transient due to acquired resistance …